Sucralfate is an aluminum complex that forms a protective coating over ulcers in the stomach and duodenum for the treatment of peptic ulcers. It reduces stomach acid and protects damaged areas from acid and pepsin. Sucralfate is also used in the treatment of gastroesophageal reflux disease (GERD).The rising prevalence of peptic ulcer disease and GERD in the U.S. is expected to drive the demand for sucralfate over the forecast period.
The global U.S. Sucralfate Market is estimated to be valued at US$ 60.8 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of peptic ulcer disease (PUD), especially among the elderly population, is augmenting demand for sucralfate. Peptic ulcers develop when the mucosal lining of the stomach or duodenum is corroded by stomach acid and pepsin. NSAIDs and H. pylori infection are leading causes of PUD. According to the Centers for Disease Control and Prevention (CDC), around 4 million Americans are affected by PUD each year. Additionally, rising diagnosis of GERD, which may lead to esophageal ulceration, is also driving the need for sucralfate treatment. GERD affects over 60 million Americans annually, thus creating robust demand for sucralfate drugs over the forecast period.
SWOT Analysis
Strength: Sucralfate is effective in healing duodenal ulcers and other acid-related ulcers in the GI tract. It acts as a protective barrier against acid and pepsin.
Weakness: Sucralfate has low solubility and dissolves slowly which reduces its absorption in the GI tract. This can lead to variability in clinical response. Frequent dosing is required.
Opportunity: Rising prevalence of peptic ulcers due to increased stress levels and consumption of NSAIDs presents an opportunity. High recurrence rate of duodenal ulcers also necessitates long term treatment options.
Threats: Increased competition from alternative therapies like PPIs and H2 receptor blockers. Generic versions erosion of sales after patent expiration of branded products.
Key Takeaways
The U.S. sucralfate market size is expected to witness moderate growth over the forecast period driven by increasing cases of peptic ulcers. The global U.S. Sucralfate Market is estimated to be valued at US$ 60.8 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030.
The Northeast region currently dominates the market due to high awareness and healthcare expenditure. States like New York and Pennsylvania have a high density of patients undergoing sucralfate therapy.
Key players operating in the U.S. sucralfate market are Allegan, Pharmaceuticals, Santa Cruz Biotechnology, Abcam, and Lannett Company. These companies have a wide product portfolio and significant market share. Strategic collaborations with regional suppliers are helping them expand geographic footprints.
The market is consolidated with the top 3 players accounting for over 75% share. Generic versions have significantly impacted prices after major patents expired in early 2010s. However, sucralfate still remains an important treatment option for certain patient groups due to its superior efficacy in healing ulcers. New formulations with enhanced solubility can further drive future adoption.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it